Anixa Biosciences (ANIX) Asset Writedowns and Impairment (2019)
Anixa Biosciences' (ANIX) quarterly Asset Writedowns and Impairment came in at $418750.0 in Q1 2019.
Anixa Biosciences (ANIX) Asset Writedowns and Impairment (2019) Analysis & Trends
Anixa Biosciences (ANIX) has 1 years of Asset Writedowns and Impairment data on file, last reported at $418750.0 in Q1 2019.
- Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $418750.0 in Q1 2019, while the trailing twelve-month figure through Oct 2019 was $418750.0 (changed N/A YoY) and the FY2019 annual result came in at $418750.0, down 28.17% from the prior year.
- Asset Writedowns and Impairment steadied at $418750.0 in Q1 2019.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $418750.0 in Q1 2019 to a low of $418750.0 in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Anixa Biosciences | 123.62 Mn | 123.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2019 | 418,750.00 |
| Jan 31, 2019 | 418,750.00 |